Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
Date:10/27/2008

CRANBURY, N.J., Oct. 27 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) will announce third quarter 2008 financial results after the regular close of markets on Monday, November 3, 2008. The results announcement will be followed by a live conference call and webcast that afternoon at 5 p.m. ET.

Interested participants and investors may access the conference call at 5 p.m. ET by dialing 877-419-6591 (U.S./Canada) or 719-325-4858 (international). A telephonic replay of the call will be available for seven days beginning at 8 p.m. ET. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 4499321.

An audio webcast can also be accessed via the investor section of the Amicus Therapeutics Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus' press releases are available at http://www.amicustherapeutics.com

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
2. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
3. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
4. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
5. Amicus Therapeutics to Host R&D Day
6. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
7. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
8. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/24/2019)... ... September 24, 2019 , ... In the past three years, the National ... at South Dakota School of Mines & Technology that expands human understanding ... surfaces to form a slimy and yet strong layer which is commonly known as ...
(Date:9/17/2019)... ... 2019 , ... Geneticure, Inc., a Rochester Minnesota company developing ... U.S. Patent and Trademark Office (USPTO) and European Patent Office (EPO) have issued ... hypertension treatment. , The patent applies to Geneticure’s first pharmacogenomics test, in ...
(Date:9/17/2019)... ... September 16, 2019 , ... MyBioGate ... China Focus @ Biotech Week Boston, a forum organized by MyBioGate, Inc. and ... innovation. , After a careful process of evaluation, twelve companies out of over ...
(Date:9/11/2019)... ... September 10, 2019 , ... Catalent, the ... biologics, gene therapies, and consumer health products, today announced that Alex Haig, Senior ... Bausparkasse Schwäbisch Hall AG, Schwabisch Hall, Germany, on Sept. 18-19, 2019. , On ...
Breaking Biology Technology:
(Date:10/3/2019)... ... October 01, 2019 , ... ... and dispensing of chemicals, reagents, and medias and to be a more environmentally ... is the culmination of years of experience and feedback from the original version ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem cells ... studying the development and diseases of the human heart, there is an increasing need ... heart muscle cells to be clearly and easily recorded. A study released today in ...
(Date:9/25/2019)... ... September 25, 2019 , ... ... through off-the-record collaboration and dialogue, today announces its inaugural South CEO ... Center in Louisiana. , Co-produced by Tulane University, this invitation-only meeting convenes ...
Breaking Biology News(10 mins):